Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPAZ trial of suprachoroidal triamcinolone acetonide plus intravitreal anti-VEGF for retinal vein occlusion
2017-002089-37Phase 3Terminated
- Sponsor
- Clearside Biomedical
- Start
- Apr 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of triamcinolone acetonide, bevacizumab and ranibizumab in Vein occlusion (RVO) (2 arms), sponsored by Clearside Biomedical. Started Apr 2018; status: terminated.
02
Drugs
triamcinolone acetonidebevacizumabranibizumab
03
Conditions
Vein occlusion (RVO)
Beyond the preview
Go deeper on 2017-002089-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002089-37.